Response to M. tuberculosis selected RD1 peptides in Ugandan HIV-infected patients with smear positive pulmonary tuberculosis: a pilot study View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2008-01-28

AUTHORS

Delia Goletti, Stefania Carrara, Harriet Mayanja-Kizza, Joy Baseke, Michael Angel Mugerwa, Enrico Girardi, Zahra Toossi

ABSTRACT

BACKGROUND: Tuberculosis (TB) is the most frequent co-infection in HIV-infected individuals still presenting diagnostic difficulties particularly in developing countries. Recently an assay based on IFN-gamma response to M. tuberculosis RD1 peptides selected by computational analysis was developed whose presence is detected during active TB disease. Objective of this study was to investigate the response to selected RD1 peptides in HIV-1-infected subjects with or without active TB in a country endemic for TB and to evaluate the change of this response over time. METHODS: 30 HIV-infected individuals were prospectively enrolled, 20 with active TB and 10 without. Among those with TB, 12 were followed over time. IFN-gamma response to selected RD1 peptides was evaluated by enzyme-linked immunospot (ELISPOT) assay. As control, response to RD1 proteins was included. Results were correlated with immune, microbiological and virological data. RESULTS: Among patients with active TB, 2/20 were excluded from the analysis, one due to cell artifacts and the other to unresponsiveness to M. tuberculosis antigens. Among those analyzable, response to selected RD1 peptides evaluated as spot-forming cells was significantly higher in subjects with active TB compared to those without (p = 0.02). Among the 12 TB patients studied over time a significant decrease (p =< 0.007) of IFN-gamma response was found at completion of therapy when all the sputum cultures for M. tuberculosis were negative. A ratio of RD1 peptides ELISPOT counts over CD4+ T-cell counts greater than 0.21 yielded 100% sensitivity and 80% specificity for active TB. Conversely, response to RD1 intact proteins was not statistically different between subjects with or without TB at the time of recruitment; however a ratio of RD1 proteins ELISPOT counts over CD4+ T-cell counts greater than 0.22 yielded 89% sensitivity and 70% specificity for active TB. CONCLUSION: In this pilot study the response to selected RD1 peptides is associated with TB disease in HIV-infected individuals in a high TB endemic country. This response decreases after successful therapy. The potential of the novel approach of relating ELISPOT spot-forming cell number and CD4+ T-cell count may improve the possibility of diagnosing active TB and deserves further evaluation. More... »

PAGES

11-11

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1471-2334-8-11

DOI

http://dx.doi.org/10.1186/1471-2334-8-11

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1000532665

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/18226199


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1108", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical Microbiology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antigens, Bacterial", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bacterial Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "CD4 Lymphocyte Count", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Enzyme-Linked Immunosorbent Assay", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Epitopes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "HIV Infections", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Interferon-gamma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mycobacterium tuberculosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pilot Projects", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Reagent Kits, Diagnostic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tuberculosis, Pulmonary", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Uganda", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Viral Load", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Translational Research Unit, Department of Experimental Research, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani \u2013 IRCCS Rome, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Translational Research Unit, Department of Experimental Research, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani \u2013 IRCCS Rome, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Goletti", 
        "givenName": "Delia", 
        "id": "sg:person.01200446072.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01200446072.99"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Translational Research Unit, Department of Experimental Research, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani \u2013 IRCCS Rome, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Translational Research Unit, Department of Experimental Research, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani \u2013 IRCCS Rome, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Carrara", 
        "givenName": "Stefania", 
        "id": "sg:person.01242720172.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01242720172.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Case Western Reserve University, Department of Medicine, Division of Infectious Diseases, Cleveland, Ohio, USA", 
          "id": "http://www.grid.ac/institutes/grid.67105.35", 
          "name": [
            "Case Western Reserve University, Department of Medicine, Division of Infectious Diseases, Cleveland, Ohio, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mayanja-Kizza", 
        "givenName": "Harriet", 
        "id": "sg:person.01116312154.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01116312154.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "TBRU, Kampala, Uganda", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "TBRU, Kampala, Uganda"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Baseke", 
        "givenName": "Joy", 
        "id": "sg:person.07625266157.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07625266157.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Case Western Reserve University, Department of Medicine, Division of Infectious Diseases, Cleveland, Ohio, USA", 
          "id": "http://www.grid.ac/institutes/grid.67105.35", 
          "name": [
            "Case Western Reserve University, Department of Medicine, Division of Infectious Diseases, Cleveland, Ohio, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mugerwa", 
        "givenName": "Michael Angel", 
        "id": "sg:person.01007524127.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007524127.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Epidemiology Unit, Department of Experimental Research, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani \u2013 IRCCS Rome, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Clinical Epidemiology Unit, Department of Experimental Research, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani \u2013 IRCCS Rome, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Girardi", 
        "givenName": "Enrico", 
        "id": "sg:person.01222655205.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01222655205.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Case Western Reserve University, Department of Medicine, Division of Infectious Diseases, Cleveland, Ohio, USA", 
          "id": "http://www.grid.ac/institutes/grid.67105.35", 
          "name": [
            "Case Western Reserve University, Department of Medicine, Division of Infectious Diseases, Cleveland, Ohio, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Toossi", 
        "givenName": "Zahra", 
        "id": "sg:person.01115163560.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01115163560.16"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/1471-2334-6-66", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037367872", 
          "https://doi.org/10.1186/1471-2334-6-66"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002510050595", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019170092", 
          "https://doi.org/10.1007/s002510050595"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1465-9921-7-56", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036548098", 
          "https://doi.org/10.1186/1465-9921-7-56"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nri1704", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005229957", 
          "https://doi.org/10.1038/nri1704"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1465-9921-8-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049800836", 
          "https://doi.org/10.1186/1465-9921-8-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/9858", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033407907", 
          "https://doi.org/10.1038/9858"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s15010-007-6114-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039438617", 
          "https://doi.org/10.1007/s15010-007-6114-z"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2008-01-28", 
    "datePublishedReg": "2008-01-28", 
    "description": "BACKGROUND: Tuberculosis (TB) is the most frequent co-infection in HIV-infected individuals still presenting diagnostic difficulties particularly in developing countries. Recently an assay based on IFN-gamma response to M. tuberculosis RD1 peptides selected by computational analysis was developed whose presence is detected during active TB disease. Objective of this study was to investigate the response to selected RD1 peptides in HIV-1-infected subjects with or without active TB in a country endemic for TB and to evaluate the change of this response over time.\nMETHODS: 30 HIV-infected individuals were prospectively enrolled, 20 with active TB and 10 without. Among those with TB, 12 were followed over time. IFN-gamma response to selected RD1 peptides was evaluated by enzyme-linked immunospot (ELISPOT) assay. As control, response to RD1 proteins was included. Results were correlated with immune, microbiological and virological data.\nRESULTS: Among patients with active TB, 2/20 were excluded from the analysis, one due to cell artifacts and the other to unresponsiveness to M. tuberculosis antigens. Among those analyzable, response to selected RD1 peptides evaluated as spot-forming cells was significantly higher in subjects with active TB compared to those without (p = 0.02). Among the 12 TB patients studied over time a significant decrease (p =< 0.007) of IFN-gamma response was found at completion of therapy when all the sputum cultures for M. tuberculosis were negative. A ratio of RD1 peptides ELISPOT counts over CD4+ T-cell counts greater than 0.21 yielded 100% sensitivity and 80% specificity for active TB. Conversely, response to RD1 intact proteins was not statistically different between subjects with or without TB at the time of recruitment; however a ratio of RD1 proteins ELISPOT counts over CD4+ T-cell counts greater than 0.22 yielded 89% sensitivity and 70% specificity for active TB.\nCONCLUSION: In this pilot study the response to selected RD1 peptides is associated with TB disease in HIV-infected individuals in a high TB endemic country. This response decreases after successful therapy. The potential of the novel approach of relating ELISPOT spot-forming cell number and CD4+ T-cell count may improve the possibility of diagnosing active TB and deserves further evaluation.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/1471-2334-8-11", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2425018", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2534760", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2667805", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1024946", 
        "issn": [
          "1471-2334"
        ], 
        "name": "BMC Infectious Diseases", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "8"
      }
    ], 
    "keywords": [
      "IFN-gamma responses", 
      "RD1 peptides", 
      "active tuberculosis", 
      "enzyme-linked immunospot", 
      "TB disease", 
      "ELISPOT counts", 
      "HIV-1-infected subjects", 
      "high TB endemic countries", 
      "smear-positive pulmonary tuberculosis", 
      "active TB disease", 
      "positive pulmonary tuberculosis", 
      "completion of therapy", 
      "TB-endemic countries", 
      "spot-forming cells", 
      "time of recruitment", 
      "Ugandan HIV", 
      "TB patients", 
      "sputum culture", 
      "pulmonary tuberculosis", 
      "tuberculosis antigens", 
      "virological data", 
      "diagnostic difficulties", 
      "endemic countries", 
      "successful therapy", 
      "cell count", 
      "HIV", 
      "tuberculosis", 
      "further evaluation", 
      "CD4", 
      "patients", 
      "pilot study", 
      "significant decrease", 
      "cell number", 
      "RD1 proteins", 
      "therapy", 
      "disease", 
      "subjects", 
      "count", 
      "cells", 
      "peptides", 
      "response", 
      "individuals", 
      "immunospot", 
      "specificity", 
      "antigen", 
      "study", 
      "protein", 
      "cell artifacts", 
      "sensitivity", 
      "RD1", 
      "assays", 
      "recruitment", 
      "time", 
      "completion", 
      "countries", 
      "decrease", 
      "control", 
      "evaluation", 
      "ratio", 
      "analysis", 
      "pilot", 
      "intact protein", 
      "presence", 
      "changes", 
      "objective", 
      "culture", 
      "novel approach", 
      "data", 
      "difficulties", 
      "number", 
      "potential", 
      "results", 
      "possibility", 
      "computational analysis", 
      "approach", 
      "artifacts", 
      "tuberculosis RD1 peptides", 
      "RD1 peptides ELISPOT counts", 
      "peptides ELISPOT counts", 
      "RD1 intact proteins", 
      "ratio of RD1", 
      "ELISPOT spot-forming cell number", 
      "spot-forming cell number"
    ], 
    "name": "Response to M. tuberculosis selected RD1 peptides in Ugandan HIV-infected patients with smear positive pulmonary tuberculosis: a pilot study", 
    "pagination": "11-11", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1000532665"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1471-2334-8-11"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "18226199"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1471-2334-8-11", 
      "https://app.dimensions.ai/details/publication/pub.1000532665"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:12", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_473.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/1471-2334-8-11"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1471-2334-8-11'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1471-2334-8-11'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1471-2334-8-11'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1471-2334-8-11'


 

This table displays all metadata directly associated to this object as RDF triples.

299 TRIPLES      22 PREDICATES      134 URIs      119 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1471-2334-8-11 schema:about N06a85983fc644aeebd3964480b1cfcf2
2 N07a6d31067524c3f8b17fed405c67537
3 N12ba4be94fe14b9eb1bc650b0a72c81d
4 N3a7fe61c6c2d43b5b7318d25012c3b10
5 N3fc9238213ba407286e9027105e25d14
6 N46d6a72faeeb47b3bab7b96f16f08bb8
7 N60b81bde613e4d77aecbff7c752c4df9
8 N8366406d14a54e7d94de9e02e123432d
9 N86f3f0fc16eb41d8ac02c9505ba06a77
10 N8be4db68390b457e9ef5ea4f42a138f0
11 Nb488cf3abe9b4b8199b572efbdb598af
12 Nc522fb57396e49d8a2e3bdc902dc4c54
13 Ncb77ebcd1738486cbe13358a1fd5e5a6
14 Nd9214bbca5ba4d66a44537f96b26d185
15 Ne088543097494f53b2bd505df8397255
16 Nf2a7c75c514e42a6b387f6a6fca6be9b
17 Nf504519cce6f48fdab2846faf60e790e
18 Nf7044d5dc88644aabcf31acc0fb39fea
19 anzsrc-for:11
20 anzsrc-for:1108
21 schema:author N99ebe6e4871c48f1996191f4620fa620
22 schema:citation sg:pub.10.1007/s002510050595
23 sg:pub.10.1007/s15010-007-6114-z
24 sg:pub.10.1038/9858
25 sg:pub.10.1038/nri1704
26 sg:pub.10.1186/1465-9921-7-56
27 sg:pub.10.1186/1465-9921-8-5
28 sg:pub.10.1186/1471-2334-6-66
29 schema:datePublished 2008-01-28
30 schema:datePublishedReg 2008-01-28
31 schema:description BACKGROUND: Tuberculosis (TB) is the most frequent co-infection in HIV-infected individuals still presenting diagnostic difficulties particularly in developing countries. Recently an assay based on IFN-gamma response to M. tuberculosis RD1 peptides selected by computational analysis was developed whose presence is detected during active TB disease. Objective of this study was to investigate the response to selected RD1 peptides in HIV-1-infected subjects with or without active TB in a country endemic for TB and to evaluate the change of this response over time. METHODS: 30 HIV-infected individuals were prospectively enrolled, 20 with active TB and 10 without. Among those with TB, 12 were followed over time. IFN-gamma response to selected RD1 peptides was evaluated by enzyme-linked immunospot (ELISPOT) assay. As control, response to RD1 proteins was included. Results were correlated with immune, microbiological and virological data. RESULTS: Among patients with active TB, 2/20 were excluded from the analysis, one due to cell artifacts and the other to unresponsiveness to M. tuberculosis antigens. Among those analyzable, response to selected RD1 peptides evaluated as spot-forming cells was significantly higher in subjects with active TB compared to those without (p = 0.02). Among the 12 TB patients studied over time a significant decrease (p =< 0.007) of IFN-gamma response was found at completion of therapy when all the sputum cultures for M. tuberculosis were negative. A ratio of RD1 peptides ELISPOT counts over CD4+ T-cell counts greater than 0.21 yielded 100% sensitivity and 80% specificity for active TB. Conversely, response to RD1 intact proteins was not statistically different between subjects with or without TB at the time of recruitment; however a ratio of RD1 proteins ELISPOT counts over CD4+ T-cell counts greater than 0.22 yielded 89% sensitivity and 70% specificity for active TB. CONCLUSION: In this pilot study the response to selected RD1 peptides is associated with TB disease in HIV-infected individuals in a high TB endemic country. This response decreases after successful therapy. The potential of the novel approach of relating ELISPOT spot-forming cell number and CD4+ T-cell count may improve the possibility of diagnosing active TB and deserves further evaluation.
32 schema:genre article
33 schema:inLanguage en
34 schema:isAccessibleForFree true
35 schema:isPartOf N215b073e672c4bf3bc109707c9e72d04
36 Na47d801d3af645ac96322c9de2308fad
37 sg:journal.1024946
38 schema:keywords CD4
39 ELISPOT counts
40 ELISPOT spot-forming cell number
41 HIV
42 HIV-1-infected subjects
43 IFN-gamma responses
44 RD1
45 RD1 intact proteins
46 RD1 peptides
47 RD1 peptides ELISPOT counts
48 RD1 proteins
49 TB disease
50 TB patients
51 TB-endemic countries
52 Ugandan HIV
53 active TB disease
54 active tuberculosis
55 analysis
56 antigen
57 approach
58 artifacts
59 assays
60 cell artifacts
61 cell count
62 cell number
63 cells
64 changes
65 completion
66 completion of therapy
67 computational analysis
68 control
69 count
70 countries
71 culture
72 data
73 decrease
74 diagnostic difficulties
75 difficulties
76 disease
77 endemic countries
78 enzyme-linked immunospot
79 evaluation
80 further evaluation
81 high TB endemic countries
82 immunospot
83 individuals
84 intact protein
85 novel approach
86 number
87 objective
88 patients
89 peptides
90 peptides ELISPOT counts
91 pilot
92 pilot study
93 positive pulmonary tuberculosis
94 possibility
95 potential
96 presence
97 protein
98 pulmonary tuberculosis
99 ratio
100 ratio of RD1
101 recruitment
102 response
103 results
104 sensitivity
105 significant decrease
106 smear-positive pulmonary tuberculosis
107 specificity
108 spot-forming cell number
109 spot-forming cells
110 sputum culture
111 study
112 subjects
113 successful therapy
114 therapy
115 time
116 time of recruitment
117 tuberculosis
118 tuberculosis RD1 peptides
119 tuberculosis antigens
120 virological data
121 schema:name Response to M. tuberculosis selected RD1 peptides in Ugandan HIV-infected patients with smear positive pulmonary tuberculosis: a pilot study
122 schema:pagination 11-11
123 schema:productId N472dfc8be9af4783a1abce8deb095be7
124 N61166e317cb64d30b6caf6f6444bd460
125 N9ccea690b8e64707ae8e828f931a7848
126 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000532665
127 https://doi.org/10.1186/1471-2334-8-11
128 schema:sdDatePublished 2021-11-01T18:12
129 schema:sdLicense https://scigraph.springernature.com/explorer/license/
130 schema:sdPublisher N453cad4b6b7e46d38c192649eff030d5
131 schema:url https://doi.org/10.1186/1471-2334-8-11
132 sgo:license sg:explorer/license/
133 sgo:sdDataset articles
134 rdf:type schema:ScholarlyArticle
135 N06a85983fc644aeebd3964480b1cfcf2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Bacterial Proteins
137 rdf:type schema:DefinedTerm
138 N07a6d31067524c3f8b17fed405c67537 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name HIV Infections
140 rdf:type schema:DefinedTerm
141 N12ba4be94fe14b9eb1bc650b0a72c81d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Female
143 rdf:type schema:DefinedTerm
144 N215b073e672c4bf3bc109707c9e72d04 schema:issueNumber 1
145 rdf:type schema:PublicationIssue
146 N3a7fe61c6c2d43b5b7318d25012c3b10 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Pilot Projects
148 rdf:type schema:DefinedTerm
149 N3f8dc835863242b489c285cb92595335 rdf:first sg:person.01116312154.95
150 rdf:rest N5e5186d075f34c33b7b32b1e89145e0e
151 N3fc9238213ba407286e9027105e25d14 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Enzyme-Linked Immunosorbent Assay
153 rdf:type schema:DefinedTerm
154 N453cad4b6b7e46d38c192649eff030d5 schema:name Springer Nature - SN SciGraph project
155 rdf:type schema:Organization
156 N46d6a72faeeb47b3bab7b96f16f08bb8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Male
158 rdf:type schema:DefinedTerm
159 N472dfc8be9af4783a1abce8deb095be7 schema:name pubmed_id
160 schema:value 18226199
161 rdf:type schema:PropertyValue
162 N592b322833d34ec49c073bbeaf287684 rdf:first sg:person.01115163560.16
163 rdf:rest rdf:nil
164 N5e5186d075f34c33b7b32b1e89145e0e rdf:first sg:person.07625266157.27
165 rdf:rest N894bb463efe64697a497056dc71786be
166 N60b81bde613e4d77aecbff7c752c4df9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Follow-Up Studies
168 rdf:type schema:DefinedTerm
169 N61166e317cb64d30b6caf6f6444bd460 schema:name dimensions_id
170 schema:value pub.1000532665
171 rdf:type schema:PropertyValue
172 N6ab207bf41d444aa9814800ae73226a1 rdf:first sg:person.01242720172.01
173 rdf:rest N3f8dc835863242b489c285cb92595335
174 N79bb7c520a40452abefb2069d5fa6c15 rdf:first sg:person.01222655205.82
175 rdf:rest N592b322833d34ec49c073bbeaf287684
176 N8366406d14a54e7d94de9e02e123432d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Reagent Kits, Diagnostic
178 rdf:type schema:DefinedTerm
179 N86f3f0fc16eb41d8ac02c9505ba06a77 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Adult
181 rdf:type schema:DefinedTerm
182 N894bb463efe64697a497056dc71786be rdf:first sg:person.01007524127.54
183 rdf:rest N79bb7c520a40452abefb2069d5fa6c15
184 N8be4db68390b457e9ef5ea4f42a138f0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name CD4 Lymphocyte Count
186 rdf:type schema:DefinedTerm
187 N99ebe6e4871c48f1996191f4620fa620 rdf:first sg:person.01200446072.99
188 rdf:rest N6ab207bf41d444aa9814800ae73226a1
189 N9ccea690b8e64707ae8e828f931a7848 schema:name doi
190 schema:value 10.1186/1471-2334-8-11
191 rdf:type schema:PropertyValue
192 Na47d801d3af645ac96322c9de2308fad schema:volumeNumber 8
193 rdf:type schema:PublicationVolume
194 Nb488cf3abe9b4b8199b572efbdb598af schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Uganda
196 rdf:type schema:DefinedTerm
197 Nc522fb57396e49d8a2e3bdc902dc4c54 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
198 schema:name Epitopes
199 rdf:type schema:DefinedTerm
200 Ncb77ebcd1738486cbe13358a1fd5e5a6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
201 schema:name Antigens, Bacterial
202 rdf:type schema:DefinedTerm
203 Nd9214bbca5ba4d66a44537f96b26d185 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
204 schema:name Tuberculosis, Pulmonary
205 rdf:type schema:DefinedTerm
206 Ne088543097494f53b2bd505df8397255 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
207 schema:name Mycobacterium tuberculosis
208 rdf:type schema:DefinedTerm
209 Nf2a7c75c514e42a6b387f6a6fca6be9b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
210 schema:name Viral Load
211 rdf:type schema:DefinedTerm
212 Nf504519cce6f48fdab2846faf60e790e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
213 schema:name Interferon-gamma
214 rdf:type schema:DefinedTerm
215 Nf7044d5dc88644aabcf31acc0fb39fea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
216 schema:name Humans
217 rdf:type schema:DefinedTerm
218 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
219 schema:name Medical and Health Sciences
220 rdf:type schema:DefinedTerm
221 anzsrc-for:1108 schema:inDefinedTermSet anzsrc-for:
222 schema:name Medical Microbiology
223 rdf:type schema:DefinedTerm
224 sg:grant.2425018 http://pending.schema.org/fundedItem sg:pub.10.1186/1471-2334-8-11
225 rdf:type schema:MonetaryGrant
226 sg:grant.2534760 http://pending.schema.org/fundedItem sg:pub.10.1186/1471-2334-8-11
227 rdf:type schema:MonetaryGrant
228 sg:grant.2667805 http://pending.schema.org/fundedItem sg:pub.10.1186/1471-2334-8-11
229 rdf:type schema:MonetaryGrant
230 sg:journal.1024946 schema:issn 1471-2334
231 schema:name BMC Infectious Diseases
232 schema:publisher Springer Nature
233 rdf:type schema:Periodical
234 sg:person.01007524127.54 schema:affiliation grid-institutes:grid.67105.35
235 schema:familyName Mugerwa
236 schema:givenName Michael Angel
237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007524127.54
238 rdf:type schema:Person
239 sg:person.01115163560.16 schema:affiliation grid-institutes:grid.67105.35
240 schema:familyName Toossi
241 schema:givenName Zahra
242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01115163560.16
243 rdf:type schema:Person
244 sg:person.01116312154.95 schema:affiliation grid-institutes:grid.67105.35
245 schema:familyName Mayanja-Kizza
246 schema:givenName Harriet
247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01116312154.95
248 rdf:type schema:Person
249 sg:person.01200446072.99 schema:affiliation grid-institutes:None
250 schema:familyName Goletti
251 schema:givenName Delia
252 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01200446072.99
253 rdf:type schema:Person
254 sg:person.01222655205.82 schema:affiliation grid-institutes:None
255 schema:familyName Girardi
256 schema:givenName Enrico
257 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01222655205.82
258 rdf:type schema:Person
259 sg:person.01242720172.01 schema:affiliation grid-institutes:None
260 schema:familyName Carrara
261 schema:givenName Stefania
262 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01242720172.01
263 rdf:type schema:Person
264 sg:person.07625266157.27 schema:affiliation grid-institutes:None
265 schema:familyName Baseke
266 schema:givenName Joy
267 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07625266157.27
268 rdf:type schema:Person
269 sg:pub.10.1007/s002510050595 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019170092
270 https://doi.org/10.1007/s002510050595
271 rdf:type schema:CreativeWork
272 sg:pub.10.1007/s15010-007-6114-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1039438617
273 https://doi.org/10.1007/s15010-007-6114-z
274 rdf:type schema:CreativeWork
275 sg:pub.10.1038/9858 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033407907
276 https://doi.org/10.1038/9858
277 rdf:type schema:CreativeWork
278 sg:pub.10.1038/nri1704 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005229957
279 https://doi.org/10.1038/nri1704
280 rdf:type schema:CreativeWork
281 sg:pub.10.1186/1465-9921-7-56 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036548098
282 https://doi.org/10.1186/1465-9921-7-56
283 rdf:type schema:CreativeWork
284 sg:pub.10.1186/1465-9921-8-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049800836
285 https://doi.org/10.1186/1465-9921-8-5
286 rdf:type schema:CreativeWork
287 sg:pub.10.1186/1471-2334-6-66 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037367872
288 https://doi.org/10.1186/1471-2334-6-66
289 rdf:type schema:CreativeWork
290 grid-institutes:None schema:alternateName Clinical Epidemiology Unit, Department of Experimental Research, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani – IRCCS Rome, Italy
291 TBRU, Kampala, Uganda
292 Translational Research Unit, Department of Experimental Research, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani – IRCCS Rome, Italy
293 schema:name Clinical Epidemiology Unit, Department of Experimental Research, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani – IRCCS Rome, Italy
294 TBRU, Kampala, Uganda
295 Translational Research Unit, Department of Experimental Research, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani – IRCCS Rome, Italy
296 rdf:type schema:Organization
297 grid-institutes:grid.67105.35 schema:alternateName Case Western Reserve University, Department of Medicine, Division of Infectious Diseases, Cleveland, Ohio, USA
298 schema:name Case Western Reserve University, Department of Medicine, Division of Infectious Diseases, Cleveland, Ohio, USA
299 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...